LIGAND PHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ligand Pharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Ligand Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$7.17M, a 30.2% increase year-over-year.
  • Ligand Pharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $45.2M, a 175% increase year-over-year.
  • Ligand Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was $52.2M.
  • Ligand Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$33.4M, a 158% decline from 2021.
  • Ligand Pharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was $57.1M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $45.2M -$7.17M +$3.1M +30.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $42.1M -$51.9M -$54.2M -2367% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-08
Q1 2024 $96.3M $86.1M +$44.2M +105% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-08
Q4 2023 $52.2M $18.2M +$35.7M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $16.5M -$10.3M -$10.7M -2643% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-08
Q2 2023 $27.2M $2.29M +$3.19M Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-08
Q1 2023 $24M $41.9M +$57.3M Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-08
Q4 2022 -$33.4M -$17.5M -$12.1M -223% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-28
Q3 2022 -$21.3M $404K -$13.3M -97.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$7.97M -$895K -$31.6M -103% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 $23.6M -$15.4M -$33.5M -185% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 $57.1M -$5.42M -$11.2M -194% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $68.3M $13.7M +$20.4M Jul 1, 2021 Sep 30, 2021 10-K 2023-02-28
Q2 2021 $47.9M $30.7M +$8.64M +39.1% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-28
Q1 2021 $39.3M $18.1M +$42.2M Jan 1, 2021 Mar 31, 2021 10-K 2023-02-28
Q4 2020 -$2.99M $5.76M +$13.1M Oct 1, 2020 Dec 31, 2020 10-K 2021-02-24
Q3 2020 -$16.1M -$6.7M +$8.55M +56.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$24.7M $22.1M +$36.5M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$61.2M -$24.1M -$690M -104% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 $629M -$7.37M +$35.1M +82.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 $594M -$15.3M -$82.6M -123% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 $677M -$14.4M -$87.6M -120% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 $764M $666M +$621M +1372% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 $143M -$42.5M $0 0% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $143M $67.4M $0 0% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 $143M $73.2M $0 0% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 $143M $45.3M $0 0% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 $143M -$42.5M -$39.4M -1259% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 $183M $67.4M +$66.3M +6309% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 $116M $73.2M +$79.3M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $37M $45.3M +$38.7M +585% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$1.64M -$3.13M -$9.47M -149% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $7.83M $1.05M -$198M -99.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 $206M -$6.17M -$29.7M -126% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 $236M $6.61M +$5.85M +776% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 $230M $6.34M -$714K -10.1% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 $231M $199M +$198M +15460% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 $32.7M $23.6M +$22M +1380% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 $10.7M $754K -$1.34M -64% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 $12M $7.06M +$5.19M +277% Oct 1, 2014 Dec 31, 2014 10-K/A 2016-11-15
Q3 2014 $6.84M $1.28M -$685K -34.9% Jul 1, 2014 Sep 30, 2014 10-K/A 2016-11-15
Q2 2014 $7.52M $1.59M -$4.5M -73.9% Apr 1, 2014 Jun 30, 2014 10-K/A 2016-11-15
Q1 2014 $12M $2.1M +$602K +40.3% Jan 1, 2014 Mar 31, 2014 10-K/A 2016-11-15
Q4 2013 $11.4M $1.87M +$806K +75.8% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-23
Q3 2013 $10.6M $1.97M +$2.16M Jul 1, 2013 Sep 30, 2013 10-K 2015-02-23
Q2 2013 $8.46M $6.09M +$8.62M Apr 1, 2013 Jun 30, 2013 10-K 2015-02-23
Q1 2013 -$165K $1.5M +$362K +32% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-23
Q4 2012 -$527K $1.06M -$3.63M -77.3% Oct 1, 2012 Dec 31, 2012 10-K/A 2014-12-12
Q3 2012 $3.1M -$194K +$3.98M +95.4% Jul 1, 2012 Sep 30, 2012 10-K/A 2014-12-12
Q2 2012 -$884K -$2.53M -$2.11M -499% Apr 1, 2012 Jun 30, 2012 10-K/A 2014-12-12
Q1 2012 $1.22M $1.13M -$8.49M -88.2% Jan 1, 2012 Mar 31, 2012 10-K/A 2014-12-12
Q4 2011 $9.72M $4.69M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-14
Q3 2011 -$4.18M +$7.67M +64.7% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-14
Q2 2011 -$422K -$139K -49.1% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-14
Q1 2011 $9.63M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-14
Q3 2010 -$11.8M Jul 1, 2010 Sep 30, 2010 10-Q/A 2012-02-10
Q2 2010 -$283K Apr 1, 2010 Jun 30, 2010 10-Q/A 2012-02-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.